Lilly Invests $6.5 B to Build API Plant in Houston
Houston, Texas – September 23, 2025 — Eli Lilly and Company (NYSE: LLY) will invest $6.5 billion to build...
Prescription, Generic, and Over-The-Counter: Drugs & Products.
Amneal Wins FDA Nod for Sodium Oxybate, Expanding Access to Narcolepsy Therapy
RIDGEWATER, N.J., September 11, 2025 – Amneal Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has...
Novo Nordisk: Ozempic® Cuts Mortality and CV Events in Real-World Study
Bagsværd, Denmark – September 18, 2025 – Novo Nordisk A/S announced landmark results from the REACH real-world study showing...
EU Approves ROMVIMZA™, First Therapy for TGCT Patients in Europe
Brussels, Belgium – September 17, 2025 – In a landmark development for rare disease patients, the European Commission (EC)...
Daiichi Sankyo and Merck Strengthen ADC Pipeline with FDA Nod
BASKING RIDGE, N.J. and RAHWAY, N.J., September 15, 2025 – Daiichi Sankyo and Merck (known as MSD outside the...
Lilly’s Oral GLP-1 Outperforms Oral Semaglutide in Phase 3 Trial
INDIANAPOLIS, Sept. 17, 2025 – Eli Lilly and Company (NYSE: LLY) announced today that its investigational oral GLP-1 receptor...
Precision Tablet Manufacturing Improved at Piramal’s Morpeth Facility
September 16, 2025 — Morpeth, United Kingdom Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO),...
Private Equity Firm GTCR to Acquire Zentiva from Advent, Expanding Pharma Reach
Prague, Czech Republic; London, UK; Chicago, US – September 11, 2025 – Zentiva, a leading European generics pharmaceutical company,...
Zhimeng Biopharma Wins Approval to Launch Phase 2 Epilepsy Trial
Shanghai, China – September 11, 2025 – Shanghai Zhimeng Biopharma, Inc. today announced that its investigational therapy CB03-154, a...
Lupin Wins U.S. FDA Approval for First Nanomi LAI Injectable
September 3, 2025 – Mumbai & Naples – Lupin Limited announced U.S. FDA approval for its Risperidone extended-release injectable...